Summary
9.62 0.37(3.95%)09/27/2024
Iovance Biotherapeutics Inc (IOVA)
Iovance Biotherapeutics Inc (IOVA)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 4.23 | -5.22 | -15.62 | 20.19 | -31.78 | 113.67 | -46.55 | -91.26 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 9.62 | |
| Open | 9.40 | |
| High | 9.75 | |
| Low | 9.28 | |
| Volume | 3,442,548 | |
| Change | 0.39 | |
| Change % | 4.23 | |
| Avg Volume (20 Days) | 4,885,702 | |
| Volume/Avg Volume (20 Days) Ratio | 0.70 | |
| 52 Week Range | 3.21 - 18.33 | |
| Price vs 52 Week High | -47.55% | |
| Price vs 52 Week Low | 199.53% | |
| Range | 2.29 | |
| Gap Up/Down | -0.20 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2,808 | |
| EBIDTA | -451,032,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 26.00 | |
| Book Value | 2.4310 | |
| Earnings Per Share | -1.8900 | |
| EPS Estimate Current Quarter | -0.4200 | |
| EPS Estimate Next Quarter | -0.3500 | |
| EPS Estimate Current Year | -1.2100 | |
| EPS Estimate Next Year | -0.6600 | |
| Diluted EPS (TTM) | -1.8900 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -164.6462 | |
| Return on asset (TTM) | -0.3448 | |
| Return on equity (TTM) | -0.6677 | |
| Revenue TTM | 1,904,000 | |
| Revenue per share TTM | 0.0080 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.9028 | |
| Revenue Enterprise Value | 2,730.7288 | |
| EBITDA Enterprise Value | -7.5961 | |
| Shares | ||
| Shares Outstanding | 279,832,000 | |
| Shares Float | 211,427,613 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.20 | |
| Insider (%) | 0.54 | |
| Institutions (%) | 89.22 | |
09/26 08:15 EST - fool.com
3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow
Iovance Biotherapeutics is laying the groundwork to start realizing lots of revenue. It also has a lot of work in progress to increase the number of patients it can help.
3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow
Iovance Biotherapeutics is laying the groundwork to start realizing lots of revenue. It also has a lot of work in progress to increase the number of patients it can help.
09/16 06:29 EST - fool.com
3 Things You Need to Know if You Buy Iovance Biotherapeutics Today
Iovance Biotherapeutics will take some time to become profitable. It will probably see its medicine approved in more places before that happens.
3 Things You Need to Know if You Buy Iovance Biotherapeutics Today
Iovance Biotherapeutics will take some time to become profitable. It will probably see its medicine approved in more places before that happens.
09/06 09:30 EST - fool.com
This Is the Biggest Risk With Iovance Biotherapeutics Stock
Iovance Biotherapeutics obtained accelerated approval for its cell therapy, Amtagvi, earlier this year. The company has begun rolling it out, and it presents a big opportunity for the business.
This Is the Biggest Risk With Iovance Biotherapeutics Stock
Iovance Biotherapeutics obtained accelerated approval for its cell therapy, Amtagvi, earlier this year. The company has begun rolling it out, and it presents a big opportunity for the business.
09/03 17:00 EST - globenewswire.com
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences:
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences:
09/02 18:15 EST - fool.com
3 Monster Biotech Stocks to Buy Before 2025
Iovance Biotherapeutics is seeing its sales ramp up for the first time. CRISPR Therapeutics has also started to bring in solid revenue.
3 Monster Biotech Stocks to Buy Before 2025
Iovance Biotherapeutics is seeing its sales ramp up for the first time. CRISPR Therapeutics has also started to bring in solid revenue.
08/27 04:36 EST - fool.com
Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years?
The Food and Drug Administration approved Iovance Biotherapeutics' first therapy, Amtagvi, in February. Amtagvi is a complicated treatment made from immune cells found in tumor biopsies.
Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years?
The Food and Drug Administration approved Iovance Biotherapeutics' first therapy, Amtagvi, in February. Amtagvi is a complicated treatment made from immune cells found in tumor biopsies.
08/16 17:00 EST - globenewswire.com
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 15, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options and restricted stock units covering an aggregate of 289,710 shares of Iovance's common stock to twenty-four new, non-executive employees.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 15, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options and restricted stock units covering an aggregate of 289,710 shares of Iovance's common stock to twenty-four new, non-executive employees.
08/14 07:15 EST - fool.com
This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics Stock
Iovance Biotherapeutics is now selling its first cell therapy, Amtagvi. Amtagvi requires significant logistical and manufacturing coordination.
This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics Stock
Iovance Biotherapeutics is now selling its first cell therapy, Amtagvi. Amtagvi requires significant logistical and manufacturing coordination.
08/11 09:00 EST - seekingalpha.com
Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)
Iovance's Q2 2024 revenue of $31.1 million surpassed analyst expectations. Amtagvi, Iovance's TIL therapy, generated $12.8 million in its first full quarter post-approval. Iovance's ongoing trials in NSCLC and endometrial cancer could expand lifileucel's market potential.
Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)
Iovance's Q2 2024 revenue of $31.1 million surpassed analyst expectations. Amtagvi, Iovance's TIL therapy, generated $12.8 million in its first full quarter post-approval. Iovance's ongoing trials in NSCLC and endometrial cancer could expand lifileucel's market potential.
08/09 12:23 EST - fool.com
Why Iovance Biotherapeutics Shares Are Soaring Today
Although only approved in February, Iovance's Amtagvi is already selling well. The drug in question also has potential as a treatment for several other types of cancer.
Why Iovance Biotherapeutics Shares Are Soaring Today
Although only approved in February, Iovance's Amtagvi is already selling well. The drug in question also has potential as a treatment for several other types of cancer.
08/09 12:20 EST - investorplace.com
Why Is Iovance Bio (IOVA) Stock Up 18% Today?
Iovance Biotherapeutics (NASDAQ: IOVA ) stock is taking a beating on Friday after the biotechnology company announced its earnings for the second quarter of the year. Iovance Biotherapeutics starts that report with adjusted earnings per share of -34 cents.
Why Is Iovance Bio (IOVA) Stock Up 18% Today?
Iovance Biotherapeutics (NASDAQ: IOVA ) stock is taking a beating on Friday after the biotechnology company announced its earnings for the second quarter of the year. Iovance Biotherapeutics starts that report with adjusted earnings per share of -34 cents.
08/09 11:20 EST - benzinga.com
Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock Surges
Iovance Biotherapeutics Inc IOVA stock is trading higher on Friday after the company issued upbeat guidance for 2024 and 2025 and better-than-expected second-quarter earnings.
Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock Surges
Iovance Biotherapeutics Inc IOVA stock is trading higher on Friday after the company issued upbeat guidance for 2024 and 2025 and better-than-expected second-quarter earnings.
08/09 10:31 EST - zacks.com
Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View
Iovance (IOVA) reports better-than-expected second-quarter results. Shares price rises on the back of encouraging product revenue guidance issued by management for 2024 and 2025.
Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View
Iovance (IOVA) reports better-than-expected second-quarter results. Shares price rises on the back of encouraging product revenue guidance issued by management for 2024 and 2025.
08/08 20:32 EST - seekingalpha.com
Iovance Biotherapeutics, Inc. (IOVA) Q2 2024 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Sara Pellegrino – Senior Vice President, Investor Relations and Corporate Communications Fred Vogt – Interim President and Chief Executive Officer Jim Ziegler – Executive Vice President-Commercial Igor Bilinsky – Chief Operating Officer Jean-Marc Bellemin – Chief Financial Officer Friedrich Finckenstein – Chief Medical Officer Brian Gastman – Executive Vice President-Medical Affairs Conference Call Participants Michael Yee – Jefferies Peter Lawson – Barclays Andrea Tan – Goldman Sachs Yanan Zhu – Wells Fargo Securities Tyler Van Buren – TD Cowen Ben Burnett – Stifel Colleen Kusy – Baird Asthika Goonewardene – Truist Reni Benjamin – Citizens JMP Operator Welcome to the Iovance Biotherapeutics Conference Call to discuss Second Quarter 2024 Results and Recent Corporate Updates. My name is Daniel and I will be your operator for today's call.
Iovance Biotherapeutics, Inc. (IOVA) Q2 2024 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Sara Pellegrino – Senior Vice President, Investor Relations and Corporate Communications Fred Vogt – Interim President and Chief Executive Officer Jim Ziegler – Executive Vice President-Commercial Igor Bilinsky – Chief Operating Officer Jean-Marc Bellemin – Chief Financial Officer Friedrich Finckenstein – Chief Medical Officer Brian Gastman – Executive Vice President-Medical Affairs Conference Call Participants Michael Yee – Jefferies Peter Lawson – Barclays Andrea Tan – Goldman Sachs Yanan Zhu – Wells Fargo Securities Tyler Van Buren – TD Cowen Ben Burnett – Stifel Colleen Kusy – Baird Asthika Goonewardene – Truist Reni Benjamin – Citizens JMP Operator Welcome to the Iovance Biotherapeutics Conference Call to discuss Second Quarter 2024 Results and Recent Corporate Updates. My name is Daniel and I will be your operator for today's call.
08/08 18:31 EST - zacks.com
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.47 per share a year ago.
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.47 per share a year ago.
08/08 16:01 EST - globenewswire.com
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024
Strong Momentum Continues for Amtagvi™ (Lifileucel) U.S. Launch with $31.1 Million in Total 2Q24 Revenue Total Product Revenue Guidance of $53-$55 Million for 3Q24, $160-$165 Million for FY24, and $450-$475 Million for FY25 SAN CARLOS, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported second quarter and first half 2024 financial results and corporate updates.
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024
Strong Momentum Continues for Amtagvi™ (Lifileucel) U.S. Launch with $31.1 Million in Total 2Q24 Revenue Total Product Revenue Guidance of $53-$55 Million for 3Q24, $160-$165 Million for FY24, and $450-$475 Million for FY25 SAN CARLOS, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported second quarter and first half 2024 financial results and corporate updates.
08/01 11:06 EST - zacks.com
Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Iovance Biotherapeutics (IOVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Iovance Biotherapeutics (IOVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
08/01 06:30 EST - fool.com
10 Best Small and Mid-Cap Stocks to Consider Buying in August
Big tech stocks cooled off in July, while smaller growth companies rallied. An anticipated rate cut could amplify this trend reversal in August and beyond.
10 Best Small and Mid-Cap Stocks to Consider Buying in August
Big tech stocks cooled off in July, while smaller growth companies rallied. An anticipated rate cut could amplify this trend reversal in August and beyond.
07/31 05:31 EST - fool.com
Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell?
An analyst from Piper Sandler recently downgraded Iovance Biotherapeutics and lowered the firm's price target on the stock The FDA approved Iovance's first drug in February, and investors still aren't sure if its commercial launch can succeed. An ongoing clinical trial could greatly expand the addressable patient population for the company's lead drug.
Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell?
An analyst from Piper Sandler recently downgraded Iovance Biotherapeutics and lowered the firm's price target on the stock The FDA approved Iovance's first drug in February, and investors still aren't sure if its commercial launch can succeed. An ongoing clinical trial could greatly expand the addressable patient population for the company's lead drug.
07/29 18:24 EST - fool.com
Why Iovance Biotherapeutics Stock Stumbled Today
An analyst downgraded his recommendation on the biotech. In spite of that, these are exciting times for Iovance.
Why Iovance Biotherapeutics Stock Stumbled Today
An analyst downgraded his recommendation on the biotech. In spite of that, these are exciting times for Iovance.